These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. Bastiaens GJH; van Meer MPA; Scholzen A; Obiero JM; Vatanshenassan M; van Grinsven T; Sim BKL; Billingsley PF; James ER; Gunasekera A; Bijker EM; van Gemert GJ; van de Vegte-Bolmer M; Graumans W; Hermsen CC; de Mast Q; van der Ven AJAM; Hoffman SL; Sauerwein RW Am J Trop Med Hyg; 2016 Mar; 94(3):663-673. PubMed ID: 26711509 [TBL] [Abstract][Full Text] [Related]
24. Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Epstein JE; Tewari K; Lyke KE; Sim BK; Billingsley PF; Laurens MB; Gunasekera A; Chakravarty S; James ER; Sedegah M; Richman A; Velmurugan S; Reyes S; Li M; Tucker K; Ahumada A; Ruben AJ; Li T; Stafford R; Eappen AG; Tamminga C; Bennett JW; Ockenhouse CF; Murphy JR; Komisar J; Thomas N; Loyevsky M; Birkett A; Plowe CV; Loucq C; Edelman R; Richie TL; Seder RA; Hoffman SL Science; 2011 Oct; 334(6055):475-80. PubMed ID: 21903775 [TBL] [Abstract][Full Text] [Related]
25. Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. Healy SA; Murphy SC; Hume JCC; Shelton L; Kuntz S; Van Voorhis WC; Moodie Z; Metch B; Wang R; Silver-Brace T; Fishbaugher M; Kennedy M; Finney OC; Chaturvedi R; Marcsisin SR; Hobbs CV; Warner-Lubin M; Talley AK; Wong-Madden S; Stuart K; Wald A; Kappe SH; Kublin JG; Duffy PE Clin Infect Dis; 2020 Sep; 71(6):1481-1490. PubMed ID: 31621832 [TBL] [Abstract][Full Text] [Related]
26. Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection. Peng X; Keitany GJ; Vignali M; Chen L; Gibson C; Choi K; Huang F; Wang R J Immunol; 2014 Aug; 193(3):1268-77. PubMed ID: 24958899 [TBL] [Abstract][Full Text] [Related]
30. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Roestenberg M; Walk J; van der Boor SC; Langenberg MCC; Hoogerwerf MA; Janse JJ; Manurung M; Yap XZ; García AF; Koopman JPR; Meij P; Wessels E; Teelen K; van Waardenburg YM; van de Vegte-Bolmer M; van Gemert GJ; Visser LG; van der Ven AJAM; de Mast Q; Natasha KC; Abebe Y; Murshedkar T; Billingsley PF; Richie TL; Sim BKL; Janse CJ; Hoffman SL; Khan SM; Sauerwein RW Sci Transl Med; 2020 May; 12(544):. PubMed ID: 32434847 [TBL] [Abstract][Full Text] [Related]
31. Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study. Stanisic DI; Fink J; Mayer J; Coghill S; Gore L; Liu XQ; El-Deeb I; Rodriguez IB; Powell J; Willemsen NM; De SL; Ho MF; Hoffman SL; Gerrard J; Good MF BMC Med; 2018 Oct; 16(1):184. PubMed ID: 30293531 [TBL] [Abstract][Full Text] [Related]
32. Protection against a malaria challenge by sporozoite inoculation. Roestenberg M; McCall M; Hopman J; Wiersma J; Luty AJ; van Gemert GJ; van de Vegte-Bolmer M; van Schaijk B; Teelen K; Arens T; Spaarman L; de Mast Q; Roeffen W; Snounou G; Rénia L; van der Ven A; Hermsen CC; Sauerwein R N Engl J Med; 2009 Jul; 361(5):468-77. PubMed ID: 19641203 [TBL] [Abstract][Full Text] [Related]
33. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies. Zenklusen I; Jongo S; Abdulla S; Ramadhani K; Lee Sim BK; Cardamone H; Flannery EL; Nguyen T; Fishbaugher M; Steel RWJ; Betz W; Carmago N; Mikolajczak S; Kappe SHI; Hoffman SL; Sack BK; Daubenberger C J Infect Dis; 2018 Apr; 217(10):1569-1578. PubMed ID: 29438525 [TBL] [Abstract][Full Text] [Related]
34. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527 [TBL] [Abstract][Full Text] [Related]
35. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. Jongo SA; Church LWP; Mtoro AT; Schindler T; Chakravarty S; Ruben AJ; Swanson PA; Kassim KR; Mpina M; Tumbo AM; Milando FA; Qassim M; Juma OA; Bakari BM; Simon B; James ER; Abebe Y; Kc N; Saverino E; Fink M; Cosi G; Gondwe L; Studer F; Styers D; Seder RA; Schindler T; Billingsley PF; Daubenberger C; Sim BKL; Tanner M; Richie TL; Abdulla S; Hoffman SL Clin Infect Dis; 2020 Dec; 71(11):2849-2857. PubMed ID: 31782768 [TBL] [Abstract][Full Text] [Related]
36. Exploring immunological mechanisms of the whole sporozoite vaccination against P. falciparum malaria. Mo AX; Pesce J; Hall BF Vaccine; 2015 Jun; 33(25):2851-7. PubMed ID: 25917675 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244 [TBL] [Abstract][Full Text] [Related]
38. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Jongo SA; Shekalaghe SA; Church LWP; Ruben AJ; Schindler T; Zenklusen I; Rutishauser T; Rothen J; Tumbo A; Mkindi C; Mpina M; Mtoro AT; Ishizuka AS; Kassim KR; Milando FA; Qassim M; Juma OA; Mwakasungula S; Simon B; James ER; Abebe Y; Kc N; Chakravarty S; Saverino E; Bakari BM; Billingsley PF; Seder RA; Daubenberger C; Sim BKL; Richie TL; Tanner M; Abdulla S; Hoffman SL Am J Trop Med Hyg; 2018 Aug; 99(2):338-349. PubMed ID: 29943719 [TBL] [Abstract][Full Text] [Related]
39. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Seder RA; Chang LJ; Enama ME; Zephir KL; Sarwar UN; Gordon IJ; Holman LA; James ER; Billingsley PF; Gunasekera A; Richman A; Chakravarty S; Manoj A; Velmurugan S; Li M; Ruben AJ; Li T; Eappen AG; Stafford RE; Plummer SH; Hendel CS; Novik L; Costner PJ; Mendoza FH; Saunders JG; Nason MC; Richardson JH; Murphy J; Davidson SA; Richie TL; Sedegah M; Sutamihardja A; Fahle GA; Lyke KE; Laurens MB; Roederer M; Tewari K; Epstein JE; Sim BK; Ledgerwood JE; Graham BS; Hoffman SL; Science; 2013 Sep; 341(6152):1359-65. PubMed ID: 23929949 [TBL] [Abstract][Full Text] [Related]
40. Safety and Differential Antibody and T-Cell Responses to the Jongo SA; Church LWP; Mtoro AT; Chakravarty S; Ruben AJ; Swanson PA; Kassim KR; Mpina M; Tumbo AM; Milando FA; Qassim M; Juma OA; Bakari BM; Simon B; James ER; Abebe Y; Kc N; Saverino E; Gondwe L; Studer F; Fink M; Cosi G; El-Khorazaty J; Styers D; Seder RA; Schindler T; Billingsley PF; Daubenberger C; Sim BKL; Tanner M; Richie TL; Abdulla S; Hoffman SL Am J Trop Med Hyg; 2019 Jun; 100(6):1433-1444. PubMed ID: 30994090 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]